- Lexaria Bioscience is a company dedicated to developing effective oral ingestion methods for drug substances that rival the rapid-delivery qualities of more health-dangerous inhaled-drug products.
- Inhalation is a particularly popular method of using tobacco and cannabis products, despite government warnings about the scientifically established dangers of doing so
- Lexaria has been boosting its profile and revenue potential through licensing agreements with other companies
- Lexaria recently announced a licensing agreement with Cannadips CBD-maker The Boldt Runners Corporation
- The agreement grants Cannadips CBD use of Lexaria’s DehydraTECH IP to improve the speed of its effectiveness and to combat the throat irritation that can accompany use of terpene-rich multi spectrum oils
Drug product consumption innovator Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) has announced a trade agreement that continues to advance the company’s revenue-building efforts through licensing its technology to other product manufacturers that can benefit from Lexaria’s DehydraTECH™ oral drug delivery IP.
The agreement announced recently provides Cannadips CBD with exclusive access rights to Lexaria’s technology for the U.S. market for 10 years, granting the ‘Original Smokeless CBD Dip Brand’ Lexaria’s fast-acting, high-absorption technology with options to expand the license to Europe, Mexico, and Canada and to renew the license for an additional five years (http://ibn.fm/8hoPO).
“This combination of superior science from Lexaria and a unique and strong branded proposition that Cannadips offers with its CBD pouch platform is a winning combination We are excited to be developing a category of products with best in class science to provide adult consumers the simple choice of a better product and a better alternative to tobacco and nicotine,” Lexaria board member Brian Quigley, who is also an adviser to The Boldt Runners Corporation (Cannadips), stated in a news release.
Lexaria has made its mission the development of swallowed drug substance consumption methods that approximate the rapid effectiveness of smoking or vaping, for example, while avoiding the dangers such drug inhalation can cause to users’ lungs. Those dangers gained new visibility during the past year as thousands of vape users fell seriously ill or died after inhaling products containing cannabis or nicotine deemed safer than tobacco smokes (http://ibn.fm/TlRbK).
The need for Lexaria’s IP has become evident as drug inhalation has become popular and has remained so despite science’s development of the means to demonstrate the dangers of smoked products, including cancers, on users’ lungs (http://ibn.fm/gVfND). Orally ingested medications and wellness products have in general been slower to act effectively on the user than inhaled substances and may ultimately enter the bloodstream in a more dilute measure than originally intended because of the body’s digestive screening mechanisms.
DehydraTECH has demonstrated its ability to speed its drug substance payloads to the bloodstream at rates much faster than un-enhanced oral ingestion. A new formulation of DehydraTECH has nearly doubled its rate of effectiveness, showing in lab testing that it can deliver cannabidiol (CBD) into the bloodstream at a rate 811 percent higher than generic industry control formulations, carrying 1,937 percent more CBD across the blood-brain barrier than generic industry control formulations (http://ibn.fm/wWvR4).
The body’s natural blood-brain barrier defense system protects our brain tissue from foreign substances, but also proves to be a deterrent for most small-molecule drugs that aim to enhance wellness through the central nervous system.
Cannadips’ American hemp-derived CBD pouches are an ideal product for pairing with DehydraTECH, offering 15 pouches with 10 mg of CBD (and no tobacco) each for oral delivery in tins similar in appearance to chewing tobacco. According to Lexaria’s news release, Cannadips uses terpene-rich multi spectrum oils as base ingredients that can cause some throat irritation. While some other products cut their terpenes to avoid the problem, DehydraTECH allows Cannadips to reduce the throat irritation while maintaining the entourage effect derived from multi-spectrum oils.
The Cannadips brand is being distributed nationally, including through Circle K convenience outlets, and are in about 5,000 stores in the United States with more in Europe.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP
MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.
For more information, visit www.MissionIR.com